A call for clinically driven experimental design in assessing neuroprotection in experimental Parkinsonism

Behavioural Pharmacology

Volumn 17, Issue 5-6, 2006, Pages 379-382

  Bezard, Erwan ^a  

^a CNRS   (France)

Author keywords

Genetic mouse models; MPTP; Parkinson's disease; Primate models; Progression

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; DOPAMINE; MINOCYCLINE; NEUROTOXIN;

CADAVER; CLINICAL FEATURE; CORPUS STRIATUM; DELAYED NEUROTOXICITY; DISEASE COURSE; DISEASE MODEL; DOPAMINERGIC NERVE CELL; GENE OVEREXPRESSION; GENETIC ENGINEERING; HUNTINGTON CHOREA; KNOCKOUT MOUSE; LEWY BODY; MACACA; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATONIGRAL DEGENERATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PRIMATES; RESEARCH DESIGN; SPECIES SPECIFICITY;

EID: 33748314622     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200609000-00003     Document Type: Review

References (27)

1. Agid Y (1991). Parkinson's disease: pathophysiology. Lancet 337:1321-1323.
2. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973). Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20:415-455.
3. Bezard E, Imbert C, Deloire X, Bioulac B, Gross C (1997). A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Brain Res 766:107-112.
4. Bezard E, Imbert C, Gross CE (1998). Experimental models of Parkinson's disease: from the static to the dynamic. Rev Neurosci 9:71-90.
5. Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, et al. (2001). Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease. J Neurosci 21:6853-6861.
6. Bezard E, Gerlach I, Moratalla R, Gross CE, Jork R (2006). 5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease. Neurobiol Dis ((2006) 23: 77-86).
7. Damier P, Hirsch EC, Agid Y, Graybiel AM (1999a). The substantia nigra of the human brain-I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D-28K immunohistochemistry. Brain 122:1421-1436.
8. Damier P, Hirsch EC, Agid Y, Graybiel AM (1999b). The substantia nigra of the human brain-II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122:1437-1448.
9. Diguet E, Fernagut PO, Wei X, Du Y, Rouland R, Gross C, et al. (2004). Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur J Neurosci 19:3266-3276.
10. Ehringer H, Hornykiewicz O (1960). Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin). im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 38:1236-1239.
11. Fahn S, Sulzer D (2004). Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 1:139-154.
12. Fernagut PO, Chesselet MF (2004). Alpha-synuclein and transgenic mouse models. Neurobiol Dis 17:123-130.
13. Fornai F, Schluter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, et al. (2005). Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci USA 102:3413-3418.
14. German DC, Schlusselberg DS, Woodward DJ (1983). Three-dimensional computer reconstruction of midbrain dopaminergic neuronal populations: from mouse to man. J Neural Transm 57:243-254.
15. Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, et al. (2003). Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 278:43628-43635.
16. Goldberg MS, Pisani A, Haburcak M, Vortherms TA, Kitada T, Costa C, et al. (2005). Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 45:489-496.
17. Group PS (2006). A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66:664-671.
18. Hassler R (1938). Zur Pathologie der Paralysis Agitans und des postenzephalitischen Parkinsonismus. J Psychol Neurol 48:387-476.
19. Hirsch EC (1999). Mechanism and consequences of nerve cell death in Parkinson's disease. J Neural Transm (Suppl) 56:127-137.
20. Hirsch EC, Faucheux B, Damier P, Mouatt-Prigent A, Agid Y (1997). Neuronal vulnerability in Parkinson's disease. J Neural Transm 50:79-88.
21. Hoehn HM, Yahr MD (1967). Parkinsonism: onset, progression and mortality. Neurology 17:427-442.
22. Hornykiewicz O (1966). Dopamine and brain function. Pharmacol Rev 18:925-964.
23. Kim RH, Smith PD, Aleyasin H, Hayley S, Mount MP, Pownall S, et al. (2005). Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6- tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci USA 102:5215-5220.
24. Perez FA, Palmiter RD (2005). Parkin-deficient mice are not a robust model of Parkinsonism. Proc Natl Acad Sci USA 102:2174-2179.
25. Prunier C, Bezard E, Mantzarides M, Besnard JC, Baulieu JL, Gross CE, et al. (2003). Presymptomatic diagnosis of experimental Parkinsonism with 123IPE2I SPECT. Neuroimage 19:810-816.
26. Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, Marler JR (2003). Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 60:1234-1240.
27. Schapira AH, Olanow CW (2004). Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 291:358-364.